Cellid Co Ltd
299660
Company Profile
Business description
Cellid Co Ltd is a research and development bioventure company. The company is developing immunotherapeutic vaccines, CeliVax. The CeliVax is a personalized vaccine which uses patient's own cells.
Contact
1 Gwanak-ro, Gwanak-gu
142 Suite 504
Korea Seoul National University Building
seoul08826
KORT: +82 232857861
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
49
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
We’ve raised our fair value estimate of Taiwan Semiconductor stock.
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,279.04 | 34.08 | -0.41% |
| DAX 40 | 25,313.15 | 39.24 | -0.15% |
| Dow JONES (US) | 49,442.44 | 292.81 | 0.60% |
| FTSE 100 | 10,219.43 | 19.51 | -0.19% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,530.02 | 58.27 | 0.25% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,944.47 | 17.87 | 0.26% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |